J. Rybakowski

Publications783
h-index55
Citations12,977
Highly Influential Citations492
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Vieta
  • 1,007 Publications • 42,081 Citations
  • M. Bauer
  • 420 Publications • 11,436 Citations
  • M. Alda
  • 374 Publications • 15,602 Citations
  • H. Akiskal
  • 616 Publications • 45,712 Citations
  • Publications
  • Influence
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
TLDR
This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year, but it cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. Expand
[Gender differences in schizophrenia].
The authors conclude that most male schizophrenic patients display poorer premorbid functioning during the early stages of the illness. They more often display structural micro-abnormalities of the… Expand
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind…
TLDR
Higher efficacy results were observed with agomelatine as compared to sertraline on both depressive and anxiety symptoms over the 6-week treatment period, together with a good tolerability profile. Expand
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.
TLDR
A consensus was reached on 12 statements on the use of antidepressants in bipolar disorder, and antidepressants should be prescribed only as an adjunct to mood-stabilizing medications. Expand
Indicators of immune activation in major depression
TLDR
The correlations between cytokines and acute phase proteins studied point to a significant role of elevated IL-6 secretion in the induction of Type I AGP microheterogeneity changes that are characteristic of some inflammatory conditions. Expand
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
TLDR
Treatment with antipsychotic medication is associated with moderate improvement in the cognitive test performance of patients who have schizophreniform disorder or who are in their first episode of schizophrenia. Expand
Determinants of objective and subjective quality of life in first-time-admission schizophrenic patients in Poland: a longitudinal study
TLDR
Because psychopathology seems to have the greatest impact on the QoL, there is a need to develop community psychosocial treatment to reduce these symptoms and to support patients in the early phase of the disease. Expand
The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness.
TLDR
The dysregulation of hypothalamic-pituitary-adrenal (HPA) axis activity, detected by DEX/CRH test is significantly more marked in patients with depression in the course of bipolar affective illness than in unipolar depression. Expand
Interleukin‐6 Serum Levels in Depressed Patients before and after Treatment with Fluoxetine
Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study
TLDR
A moderate/severe impairment of processing speed, motor dexterity, verbal memory and cognitive flexibility was found in the largest sample of FE patients analyzed so far. Expand
...
1
2
3
4
5
...